| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up † † Approved by the ESMO Guidelines Committee: June 2020. This publication supersedes the previously published version—Ann Oncol. 2012;23(suppl_7):vii131-vii138.
|
Fassnacht, M.
|
|
|
31 |
11 |
p. 1476-1490
|
artikel
|
| 2 |
Androgen deprivation therapy may constitute a more effective COVID-19 prophylactic than therapeutic strategy
|
Bennani, N.N.
|
|
|
31 |
11 |
p. 1585-1586
|
artikel
|
| 3 |
An enhanced prognostic score for overall survival of patients with cancer derived from a large real-world cohort
|
Becker, T.
|
|
|
31 |
11 |
p. 1561-1568
|
artikel
|
| 4 |
Cannabinoids as antiemetics: everything that’s old is new again
|
Warr, D.
|
|
|
31 |
11 |
p. 1425-1426
|
artikel
|
| 5 |
Corrigendum to “ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe”
|
Cherny, N.
|
|
|
31 |
11 |
p. 1589
|
artikel
|
| 6 |
Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network
|
Demetri, G.D.
|
|
|
31 |
11 |
p. 1506-1517
|
artikel
|
| 7 |
DPD testing in radical chemoradiation for anal squamous cell carcinoma
|
Jones, H.
|
|
|
31 |
11 |
p. 1580
|
artikel
|
| 8 |
Editorial Board
|
|
|
|
31 |
11 |
p. iv
|
artikel
|
| 9 |
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee
|
Michielin, O.
|
|
|
31 |
11 |
p. 1449-1461
|
artikel
|
| 10 |
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
|
Keilholz, U.
|
|
|
31 |
11 |
p. 1435-1448
|
artikel
|
| 11 |
Genetic and hormonal influence on SARS-CoV-2-infection susceptibility
|
Montopoli, M.
|
|
|
31 |
11 |
p. 1584-1585
|
artikel
|
| 12 |
Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma
|
Tetzlaff, M.T.
|
|
|
31 |
11 |
p. 1569-1579
|
artikel
|
| 13 |
Imaging-based prostate cancer screening among BRCA mutation carriers—results from the first round of screening
|
Segal, N.
|
|
|
31 |
11 |
p. 1545-1552
|
artikel
|
| 14 |
New pieces of the melanoma puzzle uncovered
|
Troiani, T.
|
|
|
31 |
11 |
p. 1430-1431
|
artikel
|
| 15 |
Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial
|
Grimison, P.
|
|
|
31 |
11 |
p. 1553-1560
|
artikel
|
| 16 |
Osimertinib in central nervous system progressive EGFR-mutant lung cancer: do we need to detect T790M?
|
Park, S.
|
|
|
31 |
11 |
p. 1582
|
artikel
|
| 17 |
Osimertinib in CNS-progressive EGFR-mutant lung cancer: do we need to detect T790M?
|
Facchinetti, F.
|
|
|
31 |
11 |
p. 1581-1582
|
artikel
|
| 18 |
Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
|
Papadimitrakopoulou, V.A.
|
|
|
31 |
11 |
p. 1536-1544
|
artikel
|
| 19 |
Pan-cancer prognostic models of clinical outcomes: statistical exercise or clinical tools?
|
Halabi, S.
|
|
|
31 |
11 |
p. 1427-1429
|
artikel
|
| 20 |
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
|
Mosele, F.
|
|
|
31 |
11 |
p. 1491-1505
|
artikel
|
| 21 |
Reply to the Letter to the Editor “Androgen deprivation therapy may constitute a more effective prophylactic than therapeutic strategy in COVID-19 patients” by N. Bennani and I. M. Bennani-Baiti
|
Zumerle, S.
|
|
|
31 |
11 |
p. 1586-1587
|
artikel
|
| 22 |
Reply to the letter to the editor: DPD testing in radical chemoradiation for anal squamous cell carcinoma? by R. Muirhead, H. Jones, D. Gilbert, A. Gilbert & C. Jacobs
|
Glynne-Jones, R.
|
|
|
31 |
11 |
p. 1587-1588
|
artikel
|
| 23 |
Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up † † These Guidelines were developed by the European Head and Neck Society (EHNS), the European Society for Medical Oncology (ESMO) and the European SocieTy for Radiotherapy & Oncology (ESTRO). The three societies nominated authors to write the guidelines as well as reviewers to comment on them. These guidelines were approved by the EHNS Executive Board, the ESMO Guidelines Committee and the ESTRO Executive Board in June 2020.
|
Machiels, J.-P.
|
|
|
31 |
11 |
p. 1462-1475
|
artikel
|
| 24 |
Survival benefits of PARP inhibitors in advanced breast cancer: a mirage?
|
Grinda, T.
|
|
|
31 |
11 |
p. 1432-1434
|
artikel
|
| 25 |
Table of Contents
|
|
|
|
31 |
11 |
p. i-ii
|
artikel
|
| 26 |
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
|
Litton, J.K.
|
|
|
31 |
11 |
p. 1526-1535
|
artikel
|
| 27 |
TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker
|
Mayer, E.L.
|
|
|
31 |
11 |
p. 1518-1525
|
artikel
|
| 28 |
The potential influence of human Y-chromosome haplogroup on COVID-19 prevalence and mortality
|
Delanghe, J.R.
|
|
|
31 |
11 |
p. 1582-1584
|
artikel
|
Tijdschrift beschrijving